ESC 365 - Expanding evidence on SGLT2i: where are we now and what can we expect?

Open Access

Expanding evidence on SGLT2i: where are we now and what can we expect?

Session: When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Topic: Treatment

Speaker: Professor S. Solomon (Boston, US)

Sponsored by PACE-CME – Supported by an unrestricted educational grant from AstraZeneca

Event: Heart Failure 2022

Congress Presentation

Add to my library

About the speaker

Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

74 presentations

29 followers

3 more presentations in this session

The clinical challenges of initiating guideline-recommended therapy in HFrEF.

Speaker: Professor J. McMurray (Glasgow, GB)

Benefits and evolving insights on SGLT2i in the spectrum of LVEF: can we set priorities?

Speaker: Professor C. Lam (Singapore, SG)

Expert panel: What are the implications for our practice?

Speaker: Professor J. McMurray (Glasgow, GB) Professor C. Lam (Singapore, SG) Professor S. Solomon (Boston, US)

Access the full session

When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Speakers: Professor S. Solomon, Professor J. McMurray, Professor C. Lam, Professor J. McMurray, Professor C. Lam...

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources